Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis.

ABSTRACT:

Background

Despite the alternatives available in metastatic colorectal cancer (mCRC), evaluating new therapies continues to be a challenge for clinicians and decision-makers. We aimed to generate a conceptual framework and establish the value criteria for evaluating treatments in mCRC and to apply this framework to assess the value of trifluridine/tipiracil (FTD/TPI) + bevacizumab (BEVA) in advanced lines of therapy for mCRC versus alternatives.

Methods

A multicriteria decision analysis (MCDA) was conducted according to the modified EVIDEM assessment framework and the following process: defining the decision problem, selecting and structuring the related criteria identified in a literature review, weighting criteria, measurement of performance, and scoring alternatives, to e

SUBMITTER: Calle C 

PROVIDER: S-EPMC12710260 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature